Company Profile

GLENMARK PHARMACEUTICALS LTD.

NSE : GLENMARKBSE : 532296ISIN CODE : INE935A01035Industry : Pharmaceuticals & DrugsHouse : Glenmark
BSE374.306.15 (+1.67 % )
PREV CLOSE (Rs.) 368.15
OPEN PRICE (Rs.) 368.75
BID PRICE (QTY) 374.30 (1 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 65676
TODAY'S LOW / HIGH (Rs.)365.10 375.65
52 WK LOW / HIGH (Rs.)356.5 711.55
NSE374.20 6.05 (+1.64 % )
PREV CLOSE(Rs.) 368.15
OPEN PRICE (Rs.) 370.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 374.20 (1198 )
VOLUME 1538093
TODAY'S LOW / HIGH(Rs.) 365.80 375.85
52 WK LOW / HIGH (Rs.)356.2 711.9

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.00
Dividend Yield(%) 0.53
TTM EPS (Rs.) 48.95
P/E Ratio 7.65
Book Value (Rs.) 431.30
Face Value (Rs.) 1
MCap (Rs. in Mn) 105615.54
Price/Earning (TTM) 7.08
Price/Sales (TTM) 1.70
Price/Book (MRQ) 0.87
PAT Margin (%) 15.77
ROCE (%) 11.02
Incorporation Year : 1977

Management Info :

Glenn Saldanha - Chairman Glenn Saldanha - Managing Director

Registered Office :

Address : B/2 Mahalaxmi Chambers,22 Bhulabhai Desai Road, ,
Mumbai,
Maharashtra-400026

Phone :

Registrar's Details : Karvy Fintech Pvt Ltd.-(Karvy Computuershare Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, MCX
NEWS More
19Aug08-19-2019$Glenmark Pharma gets nod for combination of Remogliflozin and Metformin Glenmark Pharma gets nod for

Glenmark Pharmaceuticals has received regulatory approval to market a combination of its novel, patent protected and globally-researched sodium glucose co-transporter-2 (SGLT2) inhibitor Remogliflozin etabonate (Remogliflozin) and Metformin Hydrochloride (Metformin) film coated tablets in India.

The drug is indicated in the treatment of type-2 diabetes mellitus in adults. The company will commercialize the product under the brand names ‘Remo-M’ and Remozen-M’

Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).

Glenmark Pharmaceuticals has received regulatory approval to ma..
19Aug08-19-2019$Glenmark Pharma surges on getting nod for combination of Remogliflozin and Metformin Glenmark Pharma surges on ge

Glenmark Pharmaceuticals is currently trading at Rs. 369.40, up by 8.30 points or 2.30% from its previous closing of Rs. 361.10 on the BSE.

The scrip opened at Rs. 362.00 and has touched a high and low of Rs. 372.25 and Rs. 360.00 respectively. So far 52443 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 711.55 on 10-Sep-2018 and a 52 week low of Rs. 356.50 on 16-Aug-2019.

Last one week high and low of the scrip stood at Rs. 435.00 and Rs. 356.50 respectively. The current market cap of the company is Rs. 10426.11 crore.

The promoters holding in the company stood at 46.58%, while Institutions and Non-Institutions held 38.72% and 14.71% respectively.

Glenmark Pharmaceuticals has received regulatory approval to market a combination of its novel, patent protected and globally-researched sodium glucose co-transporter-2 (SGLT2) inhibitor Remogliflozin etabonate (Remogliflozin) and Metformin Hydrochloride (Metformin) film coated tablets in India.

The drug is indicated in the treatment of type-2 diabetes mellitus in adults. The company will commercialize the product under the brand names ‘Remo-M’ and Remozen-M’

Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).

Glenmark Pharmaceuticals is currently trading at Rs. 369.40, up..
14Aug08-14-2019$Glenmark Pharmaceuticals reports 53% fall in Q1 consolidated net profit Glenmark Pharmaceuticals rep

Glenmark Pharmaceuticals has reported results for first quarter ended June 30, 2019.

The company has reported a fall of 42.67% in its net profit at Rs 227.84 crore for the quarter under review as compared to Rs 397.39 crore for the same quarter in the previous year. Total income of the company decreased marginally by 0.26% at Rs 1,567.33 crore for Q1FY20 as compared Rs 1571.40 crore for the corresponding quarter previous year.

On the consolidated basis, the company has reported a fall of 53.10% in its net profit at Rs 109.28 crore for the quarter under review as compared to Rs 232.99 crore for the same quarter in the previous year. However, total income of the company increased marginally by 0.90% at Rs 2,324.55 crore for Q1FY20 as compared Rs 2,303.83 crore for the corresponding quarter previous year.

Glenmark Pharmaceuticals has reported results for first quarter..
11Jul07-11-2019$Glenmark Pharma signs licensing agreement with Torrent Pharma Glenmark Pharma signs licens

Glenmark Pharmaceuticals and Torrent Pharmaceuticals have entered into a non-exclusive sub-licensing agreement to co-market sodium glucose co-transporter-2 (SGLT2) inhibitor, Remogliflozin Etabonate (Remogliflozin) in India.

Under the terms of the agreement, the company will receive an upfront payment, license fees and royalties for the non-exclusive sub-license rights from Torrent. The company will manufacture and supply Remogliflozin while Torrent will market the drug under its own trademark ‘Zucator’ in India.

Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).

Glenmark Pharmaceuticals and Torrent Pharmaceuticals have enter..
11Jul07-11-2019$Glenmark Pharma surges on signing licensing agreement with Torrent Pharma Glenmark Pharma surges on si

Glenmark Pharmaceuticals is currently trading at Rs. 453.20, up by 7.70 points or 1.73% from its previous closing of Rs. 445.50 on the BSE.

The scrip opened at Rs. 449.70 and has touched a high and low of Rs. 454.15 and Rs. 449.70 respectively. So far 3587 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 711.55 on 10-Sep-2018 and a 52 week low of Rs. 423.70 on 08-Jul-2019.

Last one week high and low of the scrip stood at Rs. 454.90 and Rs. 423.70 respectively. The current market cap of the company is Rs. 12570.59 crore.

The promoters holding in the company stood at 46.54%, while Institutions and Non-Institutions held 39.55% and 13.90% respectively.

Glenmark Pharmaceuticals and Torrent Pharmaceuticals have entered into a non-exclusive sub-licensing agreement to co-market sodium glucose co-transporter-2 (SGLT2) inhibitor, Remogliflozin Etabonate (Remogliflozin) in India.

Under the terms of the agreement, the company will receive an upfront payment, license fees and royalties for the non-exclusive sub-license rights from Torrent. The company will manufacture and supply Remogliflozin while Torrent will market the drug under its own trademark ‘Zucator’ in India.

Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).

Glenmark Pharmaceuticals is currently trading at Rs. 453.20, up..
Financials More
Rs. in Millions
QTR Jun 19 ANNUAL 19
Net Profit2278.4316221.12
Gross Profit 2769.44 18181.84
Operating Profit 3771.8518030.92
Net Sales 14987.9363048.67
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Dr. Reddys Lab (BSE)
 2554.90 (1.77%)
M.Cap ( in Cr)
42440.42
Astrazeneca Pharma I (BSE)
 1774.20 (2.41%)
M.Cap ( in Cr)
4435.50
Jenburkt Pharma (BSE)
 451.90 (6.33%)
M.Cap ( in Cr)
207.39
Alkem Laboratories (BSE)
 1768.85 (1.27%)
M.Cap ( in Cr)
21149.26
Everest Organics (BSE)
 179.15 (11.97%)
M.Cap ( in Cr)
143.32
Shareholding Pattern More
PROMOTERS 46.58 %
MUTUAL FUNDS/UTI 4.88 %
FI/BANKS/INSURANCE 2.62 %
NON-INSTITUTION 14.71 %
GOVERNMENT 0 %
FII 0 %
F & O Quotes